Drug news
FDA does not accept NDA for Crinone gel (Watson) for use in reducing risk of Preterm Birth
The FDA has issued a complete response to an NDA for Crinone (progesterone vaginal gel 8%), from Watson, for use in the reduction of risk of Preterm Birth in women with a singleton gestation and a short uterine cervical length in the mid-trimester of pregnancy. The letter stated that the effect of treatment with Crinone in reducing the risk of Preterm Birth in women with a short uterine cervical length at
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
3 mins